• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Rosuvastatin associated with reduction of cardiovascular disease in all ethnicities: The HOPE-3 study

byMatthew Lin, MDandShaidah Deghan, MSc. MD
May 31, 2016
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Intermediate-risk cardiovascular patients on rosuvastatin demonstrated significantly lower risk of cardiovascular events compared to patients on placebo.

2. Intermediate-risk cardiovascular patients on rosuvastatin have higher rate of muscular symptoms but lower levels of DVTs or PEs compared to placebo. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recent literature has demonstrated a continuous positive relationship between coronary disease and blood cholesterol levels. Additionally, clinical trials have shown that lowering LDL cholesterol concentrations with statins can reduce the risk of cardiovascular disease. However, previous trials that evaluated the effects of statins on reducing cardiovascular disease had typically studied racially homogenous populations that had a baseline cardiovascular disease. The HOPE-3 Trial expanded current literature by investigating whether statins had clinical benefit for an ethnically diverse and intermediate-risk patient population that did not have a baseline cardiovascular disease. The researchers found that patients treated with rosuvastatin (10mg/day), had significantly less cardiovascular events compared to placebo. Furthermore, this group had a lower risk of stroke, MI and hospitalization due to cardiovascular causes. Additionally, the researchers found that while the rosuvastatin group had significantly higher rates of muscle pain and weakness, the rate of discontinuation was actually lower for rosuvastatin compared to placebo. The HOPE-3 researchers proposed that the positive clinical effects of rosuvastatin were likely underestimated due to the trial’s relatively short mean duration and the time-to-first even analysis methodology. Overall, data from this study suggests that there is significant clinical benefit to using statins in intermediate-risk persons with low associated side effects.

Click to read the study in NEJM

Relevant Reading: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 2 randomised trials

In-Depth [randomized controlled trial]: This was a multicenter, long-term, international, double-blind, randomized, placebo-controlled trial which took place at 228 centers in 21 countries. For this study in particular the researchers had randomized 12,705 participants to either a rosuvastatin (n=6361) treatment group or a placebo group (n=6344). Men were 55 years of age and older and women who were 65 years of age and older who had at least one of the following risk factors: elevated waist-to-hip ratio, history of low level high-density lipoprotein cholesterol, current or recent tobacco use, dysglycemia, family history of premature coronary disease or mild renal dysfunction. Of note, women between 60-64 years of age were included if they have at least two of the aforementioned risk factors. Patients with cardiovascular diseases were excluded and the study took place between April 2007 through November 2010 with a median follow-up of 5.6 years. With regards to adherence, placebo was discontinued at a significantly higher rate compared to rosuvastatin (23.7% vs. 26.2%; p=0.001). Overall, mean LDL cholesterol was 26.5% lower in the rosuvastatin group compared to placebo. End-trial LDL cholesterol levels were significantly lower in the rosuvastatin group compared to the placebo group (difference of 34.6mg/dL or 26.5%; p<0.001) as were mean triglyceride levels (0.24mmol/L difference; p<0.001) and CRP levels (log-transformed mean difference=0.19mg/L; p<0.001).

RELATED REPORTS

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

Wellness Check: Mental Health

Composite of death due to cardiovascular etiology, nonfatal MI or stroke occurred in 3.7% of the rosuvastatin participants compared to 4.8% of the placebo participants (HR=0.76; 95% [CI]=0.64-0.91; p=0.002). The NNT with rosuvastatin to prevent this composite was 91. The cumulative incidence of nonfatal strokes was significantly lower in the rosuvastatin participants (HR=0.7; 95%[CI]=0.52-0.95; p=0.02). Furthermore, nonfatal MIs occurred significantly less in the treatment group compared to the placebo participants (HR=0.65;95%[CI]=0.44-0.94; p=0.02). Rosuvastatin participants had significantly fewer hospitalizations due to cardiovascular causes compared to placebo (4.4% vs. 5.8%; HR=0.75; 95%[CI]=0.64-0.88; p<0.001). With regards to adverse effects, the rosuvastatin group had significantly more muscle symptoms (5.8% of participants vs. 4.7% in placebo group; p=0.005) and fewer DVTs/PEs compared to the placebo group ((14 vs. 31; HR=0.45;95%CI=0.24-0.84; p=0.01). Interestingly, there was no significant difference in the number of participants in whom the assigned treatment was permanently discontinued because of muscle symptoms. 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Heat-killed environmental bacteria may improve stress responses in mice [PreClinical]

Next Post

Antihypertensives not linked to decreased cardiovascular events: The HOPE-3 trial

RelatedReports

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
StudyGraphics

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma

May 20, 2022
Exercise intervention linked to reduced functional decline among elderly patients admitted to the hospital
Wellness

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

May 20, 2022
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women
Wellness

Wellness Check: Mental Health

May 19, 2022
#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Next Post
UTI associated with increased risk of preeclampsia

Antihypertensives not linked to decreased cardiovascular events: The HOPE-3 trial

Neurocognitive deficits in congenital heart disease may not worsen with age

Neurocognitive deficits in congenital heart disease may not worsen with age

HOSPITAL score predicts risk of 30-day potentially avoidable readmission to hospital

Hospital mobility program linked to preserved mobility following in-patient admission

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.